Boundless Bio, Inc.

Boundless Bio, Inc. (BOLD), a clinical-stage oncology company, reported a net loss of $58.2 million for FY 2025, improved from $65.4 million in FY 2024, driven by a 13% reduction in operating expenses to $63.6 million. No revenue was generated as the company remains pre-commercial with no approved products. Research and development expenses decreased 19% to $44.8 million, primarily from reduced spending on discontinued trials like POTENTIATE and STARMAP, offset by BBI-940 investments. General and administrative expenses rose slightly 4% to $18.7 million due to facilities costs. Cash used in operations improved to $46.7 million from $60.8 million, supported by $37.8 million net investing inflows from investment maturities. Balance sheet shows $157.1 million total assets, $109.6 million current assets including $17.9 million cash equivalents and $89.7 million short-term investments, with $98.7 million stockholders' equity. Post-IPO cash runway extends into H2 2028, funding BBI-940 Phase 1 KOMODO-1 trial expecting initial data. Portfolio prioritization discontinued other ecDTx programs, focusing resources on lead asset amid ongoing losses and $259.7 million accumulated deficit.

Key Takeaways